Strattera
Brand name for atomoxetine, a non-stimulant ADHD medication
As defined in Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
Where it comes up · 1
Most important claims · 9 of 9Search all claims for “Strattera” →
- In a comparative study of Strattera versus Qelbree, 85% of patients who had Qelbree added to their stimulant medication were able to taper off the stimulant after stabilizing on Qelbree, indicating that Qelbree alone was sufficient for many patients.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- A 2023 comparative study found that viloxazine (Qelbree) was more effective than atomoxetine (Strattera) and worked faster, showing effects within about one week for children and two weeks for adults.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- Atomoxetine (Strattera) and viloxazine (Qelbree) are both norepinephrine reuptake inhibitors that work by increasing norepinephrine in the prefrontal cortex, which secondarily increases dopamine and serotonin in that brain region.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- Atomoxetine (Strattera) can take a month or more to reach good therapeutic effect.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- Unlike stimulants, atomoxetine (Strattera) and viloxazine (Qelbree) must be taken daily because they require consistent dosing to maintain their effects.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- Viloxazine (Qelbree) is still a brand-name medication, which means doctors often need to complete insurance authorizations for coverage, and some insurances require patients to try and fail atomoxetine (Strattera) first before approving viloxazine.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- Atomoxetine (Strattera) was the first non-stimulant medication approved for ADHD in both children and adults in 2002, making it over 20 years old as a treatment option.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- There are currently four FDA-approved non-stimulant medications for ADHD: clonidine (Kapvay), guanfacine (Intuniv), atomoxetine (Strattera), and viloxazine (Qelbree, approved in 2021).Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- Based on Dr. Marks' clinical experience, atomoxetine (Strattera) produced only so-so results in adult patients, with stimulants always seeming to work better and faster.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication